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Abstract
Background: An inverse relationship between the level of high-density lipoprotein (HDL) and
coronary heart disease (CHD) has been reported. In contrast, oxidized HDL (oHDL) has been
shown to induce neuronal death and may play an important role in the pathogenesis of CHD. In
the present study we have investigated a: the effect of various equine estrogens on HDL oxidation,
b: the inhibition of LDL oxidation by HDL and c: the effect of these estrogens on LDL oxidation in
the presence of HDL.
Results: All 11 equine estrogens tested protected the HDL from oxidation in a concentration
dependant manner. Equilenin, 17β-dihydroequilenin, and 17α-dihydroequilenin (∆6–8-estrogens)
were found to be the most potent inhibitors of HDL oxidation. Some of the novel ring B
unsaturated estrogens were 2.5 to 4 times more potent inhibitors of HDL oxidation than 17β-
estradiol. HDL was found to delay LDL oxidation. The protection of LDL oxidation by HDL is
enhanced by the addition of estrogen, with equilenin being again more potent than 17β-estradiol.
Conclusions: Equine estrogens can differentially inhibit the oxidation of HDL with the ∆6–8-
estrogens being the most potent antioxidants. The ability of estrogens to enhance HDL's
antioxidant activity is to our knowledge the first report of an interaction of estrogen with HDL that
results in the delay or inhibition of LDL oxidation. This may be another mechanism by which
estrogens may reduce the risk of CHD and neurodegenerative diseases in healthy and younger
postmenopausal women.
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Background
Oxidatively modified lipoproteins, such as oxidized low-
density lipoprotein (oLDL) have been implicated in the
pathogenesis of atherosclerosis and neurodegenerative
diseases such as Alzheimer's disease (AD) [1–5]. This per-
oxidation of the low-density lipoprotein (LDL) molecule
renders it immunogenic and causes monocyte recruit-
ment, foam cell formation and cytotoxicity to various cells
including neurons [6–8].
In contrast, epidemiological data has suggested a strong
inverse correlation between plasma HDL concentrations
and the incidence of coronary and cerebral atherosclerosis
[9,10]. Traditionally, this relationship has been proposed
to be due in part to the involvement of HDL in reverse
cholesterol transport, however, recent studies have shown
that HDL can prevent the oxidation of LDL [11]. This pre-
vention of LDL oxidation by HDL contributes to a
decrease in the formation of lipid peroxides, foam cell for-
mation and cytotoxicity otherwise caused by oLDL [12–
14]. Recent evidence suggests that HDL associated
enzymes such as paroxonase, may play a critical role in
this protective effect [15,16]. However, HDL itself can get
oxidized and the ability of oxidized HDL (oHDL) in
reverse cholesterol transport is impaired [17]. Further-
more, oHDL is neurotoxic and has been postulated to play
a role in the genesis of coronary artery spasm that contrib-
utes to the process of CHD [8,18].
Epidemiological studies have indicated that premenopau-
sal women have a decreased risk for the development of
atherosclerosis when compared to that of age-matched
males, however, this decreased risk diminishes following
menopause [19]. It has therefore been suggested that
ovarian hormones, such as estrogen, play a role in the
decreased risk observed in premenopausal women. Dur-
ing menopause, plasma LDL and HDL levels increase and
decrease respectively, however studies have shown that
estrogen replacement therapy (ERT) and hormone
replacement therapy (HRT, estrogen plus progestin) alter
these levels [20,21], in that serum total cholesterol and
LDL cholesterol decreases while HDL cholesterol
increases [22]. Until recently the modification of the
plasma LDL:HDL ratio was thought to be the main mech-
anism for the cardioprotective effects of estrogen
observed, however, recent evidence indicates that these
play a minor role [23]. More recently, it has been observed
that various equine estrogens can also differentially
inhibit the oxidation of the LDL and can attenuate the
cytotoxicity of oLDL on neuronal cells [8,24].
In the present study, the effects of various equine estro-
gens on the oxidation of HDL and the combined effect of
estrogen and HDL on LDL oxidation was assessed. The
equine estrogens tested in this study were: estrone (E1),
17β-estradiol (17β-E2), 17α-estradiol (17α-E2), equilin
(Eq), 17β-dihydroequilin (17β-Eq), 17α-dihydroequilin
(17α-Eq), equilenin (Eqn), 17β-dihydroequilenin (17β-
Eqn), 17α-dihydroequilenin (17α-Eqn), ∆8-estrone (∆8-
E1), and ∆8,17β-estradiol (∆8,17β-E2). All estrogens tested,
with the exception of ∆8,17β-E2 (a metabolite of ∆8-E1), in
their sulfate-conjugated form, are components of the con-
jugated equine estrogens (CEE; Premarin®, Wyeth Phar-
maceuticals, Philadelphia, PA), commonly used by
postmenopausal women for ERT and HRT. The structural
differences between these estrogens are depicted in Figure
1.
Results
Oxidation of HDL in the presence and absence of various 
estrogens
The effects of various concentrations of equine estrogens
on the kinetics of HDL oxidation induced by Cu2+ were
determined as described in the methods. Representative
examples of dose-response curves obtained with the vari-
ous estrogens are shown in Figure 2. Three phases of diene
formation were observed in all control samples: an initial
induction phase (lag phase), a propagation phase and a
decomposition phase (plateau). During the induction
phase, the formation of dienes progressed slowly. In the
propagation phase, a sharp, linear increase in diene for-
mation was noted and the plateau phase was followed by
a slow increase due to decomposition of products. The lag
time for control was 65 ± 4 min, and in presence of estro-
gens, it ranged from 75 to 244 min.
All 11 estrogens tested protected the HDL from oxidation
and increased the lag phase in a concentration dependant
manner. The results obtained for each of the highest con-
centration of estrogen tested were expressed as percent of
17β-E2 antioxidant activity (lag time for the highest 17β-
E2 concentration used was set to 100%, Figure 3). In the
presence of 17β-E2  (0.5  µg, 610 nM) the lag phase
increased from a control lag phase of 65 ± 4 min for HDL
alone, to 212 ± 4 min (P < 0.001). Similarly, Eqn (0.05 µg,
62.5 nM) increased the lag phase to 200 ± 16 min, as com-
pared to the mean control value of 65 ± 4 min (P < 0.001).
This differential effect was observed with most of the
estrogens tested such that the order of antioxidant activity
from the most potent to least potent was: Eqn = 17α-Eqn
> 17β-Eqn > ∆8,17β-E2 = ∆8-E1 > 17α-Eq = 17β-Eq = 17β-
E2 > E1 = Eq > 17α-E2.
The ∆6–8 ring B unsaturated equine estrogens, Eqn, 17β-
Eqn and 17α-Eqn, were found to be the most potent
inhibitors of HDL oxidation having two- to four-fold
higher activity than 17β-E2. Similarly, ∆8-E1 and ∆8,17β-E2
were found to have 150% greater antioxidant activity than
control. 17α-Eq and 17β-Eq were found to be equipotent
with 17β-E2, while Eq, E1 and 17α-E2 were found to be lessLipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/4
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potent, with activities ranging from approximately 60 to
70% that of 17β-E2 (Figure 3).
The minimum concentration of estrogen required to dou-
ble the lag phase from a mean (control) lag time of 65 ± 4
min are listed in Table 1. Eqn, 17α-Eqn, 17β-Eqn and
∆8,17β-E2 all required approximately 50 to 80 nM to dou-
ble the lag phase. In contrast, 17α-Eq, 17β-Eq, Eq, 17β-E2,
E1, and 17α-E2 all required approximately 210 to 360 nM
concentrations to double the lag phase.
LDL oxidation in the presence of HDL alone and in the 
presence of HDL with estrogen
The mean control lag phase for oxidation of LDL alone
was observed to be 73 ± 1.3 min. When LDL was subjected
to oxidation in the presence of HDL the lag phase was pro-
longed to 104.5 ± 7 min (P < 0.001) (Figure 4). The results
indicate that 17β-E2  in the presence of HDL further
enhances the inhibition of LDL oxidation than that
attained with 17β-E2 alone (Figure 5a). Thus, treatment of
LDL with 17β-E2 (0.5 µg, 610 nM) alone prolonged the
control oxidation lag time to approximately 140.5 min,
while 17β-E2 plus HDL treatment prolonged the oxidation
Structure of equine estrogens Figure 1
Structure of equine estrogens. With the exception of ∆8,17β-estradiol, all estrogens in their sulfated form are components 
present in the estrogen replacement drug CEE (conjugated equine estrogens; Premarin®, Wyeth Pharmaceuticals, PA, USA).
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lag time to 251.5 min. A similar effect was observed with
Eqn (0.5 µg, 625 nM), however, the combination of Eqn
plus HDL completely inhibited the lag phase of LDL oxi-
dation, while Eqn alone prolonged the lag phase of LDL
oxidation to greater than 300 min (Figure 5b). Eqn was
observed to be more effective at prolonging LDL oxida-
tion lag phase in combination with HDL than 17β-E2 in
combination with HDL (Figure 5b).
Discussion
In the present study, we assessed the rate of oxidation of
lipoproteins by monitoring continuously the formation
of conjugated dienes. The oxidation lag time is a measure
of the initial resistance of lipoproteins to oxidation, in our
case HDL, and has originally been used for LDL oxidation
[25]. The kinetics of HDL oxidation have been previously
shown to be mechanistically similar to LDL oxidation
[26].
A previous ex vivo study by Meng [27] and colleagues has
shown that the incorporation of very high concentrations
of esterified estrogen into HDL can prolong the oxidation
lag time of HDL, whether the concentrations of estrogens
incorporated inside HDL necessary for protection can be
attained in vivo, remains to be determined. In our present
study, we found that oHDL formation can be inhibited by
all of the 10 known components of CEE and ∆8,17β-E2, an
in vivo metabolite of ∆8-E1 [28]. In contrast to the estrogen
Representative concentration-response curves of conjugated-diene formation for various estrogen concentrations against HDL  oxidation Figure 2
Representative concentration-response curves of conjugated-diene formation for various estrogen concentrations against HDL 
oxidation. (A) 17β-E2, (B) 17β-Eqn (C) E1 (D) ∆8-E1.
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Antioxidant activity of various estrogens measured against the antioxidant potential of 17β-E2 Figure 3
Antioxidant activity of various estrogens measured against the antioxidant potential of 17β-E2. For comparison purposes the 
17β-E2 value was set at 100%.
Table 1: Dose of Estrogen Required to Double the Lag Phase of HDL oxidation
Estrogen Dose of Estrogen (nM)
17α-Estradiol 360
Equilin 320
Estrone 310
17β-Estradiol 210
17β-Dihydroequilin 210
17α-Dihydroequilin 210
∆8-Estrone 80
∆8,17β-Estradiol 80
17β-Dihydroequilenin 63
17α-Dihydroequilenin 53
Equilenin 53
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incorporation study by Meng et al [27], we have found
that in our system antioxidant protection is possible with
estrogen concentrations as low as 31 nM. A previous phar-
macokinetic study [29] has shown that circulating estro-
gen levels following a single oral dose of CEE (2 × 0.625
mg) are > 70 ng/hr/mL, and thus daily pharmacological
doses of CEE during ERT or HRT can provide sufficient
plasma estrogen levels needed to prevent the oxidation of
HDL to the extent we have observed in our in vitro study.
Under our experimental conditions, esterification of
estrogens was not possible, indicating that inhibition of
HDL oxidation by estrogens does not require prior esteri-
fication of estrogens.
We have observed that estrogens differentially inhibit
HDL oxidation. For example, Eq, 17β-Eq, and 17α-Eq all
displayed antioxidant activities similar to 17β-E2, whereas
the ∆6–8 and ∆8-estrogens had two- to four-fold greater
activities. This difference is most likely due to the extra
double bonds in the B ring, thus making the molecule
more labile and therefore able to scavenge any free
radicals produced more readily. For example, the ring B
unsaturated estrogens were more potent antioxidants
than the classical estrogens tested. Previous reports have
demonstrated that the free radical scavenging activity of
estrogen depends upon the phenolic structure of the mol-
ecule [30–32]. In addition to this, our observations indi-
cate that the presence of a β-napthol ring, such as that in
the ∆6–8 estrogens, may play a larger role in the antioxi-
dant potential observed in these types of estrogens as they
were found to be the most potent antioxidants. Thus, our
results further extend the observation that the presence of
the phenolic A ring and the 3-hydroxyl group is required
for steroid antioxidant activity, but unsaturation in the B
ring of the steroid moiety greatly enhances estrogens' anti-
oxidant potency.
Conjugated-diene formation during oxidation of LDL in the presence of HDL Figure 4
Conjugated-diene formation during oxidation of LDL in the presence of HDL. (Closed triangle) 20 µg LDL alone, (Open circle) 
20 µg LDL + 200 µg HDL.
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The order of oxidative protection for estrogens tested does
not appear to involve estrogen receptors as the relative
binding affinities to estrogen receptor (ER) α and β do not
correlate with their antioxidant activity. For instance,
compared to 17β-E2, the relative binding affinities for the
ring B unsaturated estrogens: Eq, Eqn, ∆8-E1 and 17α-Eqn
are 2 to 8 times lower for both ERs [33], whereas these
same estrogens with the exception of Eq displayed the
highest antioxidant potentials. Moreover, this order of
antioxidant activity does not correlate with their utero-
tropic activities as reported earlier [24,28,34].
In the current study we have demonstrated that HDL can
prolong the oxidation lag time of LDL using the conju-
gated diene formation method. This increase in oxidation
lag time is most likely due to the 10-fold higher concen-
tration of HDL over LDL as lower concentrations of HDL
did not provide any protection (data not shown). Simi-
larly, a study by Huang et al [35] showed HDL protection
of LDL is concentration dependant. One possible mecha-
nism for this protective effect is that HDL is preferentially
oxidized over LDL and can act as a sink for harmful lipid
peroxides [14,36]. However, a more current hypothesis is
that HDL associated enzymes such as paroxonase, and
even the apolipoprotein Apo-A1, provide HDL with its
Conjugated-diene formation during oxidation of LDL in the presence of HDL and Estrogen Figure 5
Conjugated-diene formation during oxidation of LDL in the presence of HDL and Estrogen. (A) 0.5 µg 17β-E2 + 200 µg HDL, 
(B) 0.5 µg Eqn + 200 µg HDL.
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antioxidant activity toward LDL oxidation. In support of
this hypothesis, it has been shown that incubation of LDL
with purified paroxonase inhibits lipid peroxidation
[16,37]. Furthermore, HDL apolipoproteins have also
been demonstrated to inhibit oxidative modifications of
LDL [38]. Equine estrogens have recently been shown to
stimulate the expression of Apo-A1 mRNA and protein
levels by an estrogen receptor independent mechanism.
Moreover, in these studies Eqn was also the most potent
stimulator of Apo-A1 gene expression [39]
In addition to the protective effect of HDL on LDL oxida-
tion, we have also observed that the prolongation of LDL
oxidation with HDL can be enhanced with the addition of
estrogen. Treatment with 17β-E2 plus HDL was more pro-
tective than 17β-E2 or HDL alone against LDL oxidation.
Similarly, treatment with Eqn plus HDL displayed a
greater protection against LDL oxidation than either of the
constituents alone. In line with the previously defined
order of protection, the Eqn plus HDL combination was
observed to have a greater antioxidant effect than the 17β-
E2 plus HDL combination against LDL oxidation. Also,
the increased protection by the estrogen plus HDL treat-
ment on LDL oxidation is not simply the sum of lag times
with HDL or estrogen alone on LDL oxidation, and thus is
suggestive of an interaction between estrogen and HDL.
This estrogen enhancement of HDL's antioxidant activity
is to our knowledge the first reported interaction of estro-
gen with HDL that causes a delay or inhibition of LDL oxi-
dation. Recently it has been observed that HDL3 is a more
effective antioxidant than HDL2 [40]. Following ERT, the
main HDL subfraction that is found to increase, is HDL2
[22]. More studies are needed to determine the role of
each HDL subfraction in presence of estrogen on the inhi-
bition of LDL oxidation.
Although the mechanisms involved in the antioxidant
properties of estrogen have not been fully defined, a
number of hypotheses have been put forth. Estrogens
acting as free radical scavengers are able to break the free
radical chain formation produced from membrane oxida-
tion processes and hence inhibit lipid peroxidation. In
support of this, it has been postulated that estrogen may
be able to sequester metal ions or donate a proton to
reduce peroxy-free radicals [41]. Furthermore, the stimu-
lation of Apo-A1 by estrogen may also be of importance
[39]. Thus acting as antioxidants directly and by the up-
regulation of antioxidant factors may be two additional
mechanisms that may be involved in the cardio- and neu-
roprotective effects of estrogen.
In conclusion, these results indicate that HDL oxidation
can be differentially inhibited by equine estrogens with
the three ∆6–8 ring B unsaturated equine estrogens (Figure
1, Figure 3) being three to four times more potent than
17β-E2. Furthermore, the protection of LDL oxidation by
HDL is enhanced in the presence of 17β-E2 and more so
by Eqn. The inhibition of HDL oxidation and the
enhancement provided by estrogen toward the inhibition
of LDL oxidation may therefore be another mechanism by
which estrogens reduce the risk of CHD and neurodegen-
erative diseases in healthy young postmenopausal
women.
Materials and Methods
Lipoprotein Isolation
This study has been approved by the Research Ethics
Board of St. Michael's Hospital and the University of
Toronto. Blood (10 mL) was drawn by venipuncture into
vacutainer tubes containing ethylenediaminetetraacetic
acid (EDTA; 1 mg/mL) from fasting (overnight), postmen-
opausal women and healthy men. None of the subjects
used were on any hormone therapy. The plasma was sta-
bilized by addition of 6 mg/ml sucrose and either used
immediately for lipoprotein isolation or stored at -80C for
up to four weeks as described previously [42]. HDL (d =
1.063-1.21 g/mL) and LDL (d = 1.019-1.063 g/mL) were
isolated simultaneously by a three gradient, single-step
ultracentrifugation as described previously [43]. Follow-
ing ultracentrifugation the lipoprotein containing frac-
tions (yellow-orange/colour) were collected by aspiration.
Crude HDL was further purified by re-ultracentrifugation.
Assessment of absorbance at 200 to 300 nm of the crude
and purified preparations of HDL, indicated that the
crude preparation was essentially similar to the purified
preparation and thus the single step method of isolation
was used for the experiments described. The LDL isolated
by this method had properties similar to those previously
described [24]. The freshly isolated lipoproteins were
stored at 4C under argon and used within 1 week of prep-
aration. Prior to oxidation, EDTA was removed from the
lipoprotein isolate by rapid gel filtration through dispos-
able desalting columns (ECONO-PAC 10 DG, Bio-Rad
Laboratories). The concentration of protein in each lipo-
protein isolate was measured using the Bradford method
(Bio-Rad Protein Assay kit, catalog number 500–0006,
Mississauga, ON, Canada) [44].
HDL oxidation in the presence and absence of various 
concentrations of estrogens
Oxidation of 50 µg HDL was induced by addition of 1.67
µM CuSO4 in the presence or absence of 0.025 µg, 0.05 µg,
0.25 µg, 0.5 µg, 1 µg of the 11 estrogens. The kinetics of
lipoprotein oxidation were assessed by measuring the rate
of formation of conjugated dienes measured at 234 nm
over a period of 6 hours at 32C. Absorbance was meas-
ured in a Beckman DU 640 spectrophotometer equipped
with a six-position cuvette changer and a Peltier tempera-
ture controller (Beckman Instruments, Mississauga, ON,
Canada) essentially as previously described [8,25]. TheLipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/4
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extent of lipoprotein oxidation was confirmed by assess-
ing the electrophoretic mobility of oHDL and oLDL on a
1% agarose gel in 0.1 M Tris, pH 8.6 compared to the
native form of HDL and LDL [3,8,45,46].
LDL oxidation in the presence of HDL and estrogen plus 
HDL
Oxidation of 20 µg LDL was induced in a similar manner,
however, in this case the effect of 200 µg HDL and the
combination of 17β-E2 plus 200 µg HDL or Eqn plus 200
µg HDL on LDL oxidation were assessed.
Analysis of data
The oxidation lag phase, defined as the point at which the
initial slope representing the initiation rate and the point
at which the propagation slope intersect, was calculated
from the kinetic plot of the change in absorbance versus
time as described previously [8,25,42]. From the dose
response curves, the concentration of each estrogen (nM)
required to double the length of the control lag time of
oxidation, was calculated. For comparison purposes, all
values obtained were adjusted to percent activity of 17β-
E2.
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